Coya Therapeutics, Inc. announced the appointment of Arun Swaminathan, Ph.D. to the role of Chief Business Officer. In this role, Arun will be responsible for facilitating new business development partnerships, including in/out licensing opportunities, across the Company's pipeline. Dr. Swaminathan comes to Coya with over 20 years of hands-on healthcare business executive experience with an emphasis on corporate and business development, strategy, and finance.

He possesses a demonstrated history of prospecting, evaluating, structuring, and closing company validating transactions. Prior to joining Coya, Dr. Swaminathan served as Chief Business Officer (CBO) for Actinium Pharmaceuticals, where he was responsible for all business development including out-licensing, in-licensing and other creative value generating options. Within one year of joining Actinium, he successfully moved forward negotiations to closure and executed a $452 million deal with $35 million upfront payment.

Prior to Actinium, he was the chief business officer at Alteogen, where he spearheaded over $6 billion in deals, including with two of the top 10 global pharma companies and a $1 billion+ deal within the first year of assuming the role of CBO. Prior to this, he co-founded and served as CEO of Lynkogen Inc. Dr. Swaminathan began his career in clinical development and commercial roles of increasing responsibility at Bristol Myers Squibb and Covance. He obtained his Ph.D. in pharmaceutical sciences from University of Pittsburgh.